Johannes Brägelmann

This paper develops an endothelial graft-enhanced CAM tumor model to study T cell recruitment and activation in human cancer immunotherapy.

This study identifies NMD inhibition as a therapeutic strategy for SCLC by enhancing immunogenicity and improving immunotherapy efficacy through increased neoantigen presentation.

The paper models how population growth and ROS levels interact to determine ferroptosis sensitivity, revealing feedback loops and steady states in cellular behavior.

ESM-Effect is a fine-tuning framework for predicting mutation functional effects, achieving state-of-the-art performance and faster training than multi-modal methods.

This study shows oncogenic RAS signaling suppresses ferroptosis by upregulating GCH1 and BH4, making RAS-driven cancers resistant to ferroptosis-inducing agents.